CN108368148B - 5-氮杂胞苷的糖部分甲硅烷基醚衍生物 - Google Patents

5-氮杂胞苷的糖部分甲硅烷基醚衍生物 Download PDF

Info

Publication number
CN108368148B
CN108368148B CN201680072731.4A CN201680072731A CN108368148B CN 108368148 B CN108368148 B CN 108368148B CN 201680072731 A CN201680072731 A CN 201680072731A CN 108368148 B CN108368148 B CN 108368148B
Authority
CN
China
Prior art keywords
azacytidine
compound
group
deoxy
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680072731.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN108368148A (zh
Inventor
酒向孙市
杉山晋平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohara Pharmaceutical Co Ltd
Original Assignee
Ohara Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohara Pharmaceutical Co Ltd filed Critical Ohara Pharmaceutical Co Ltd
Publication of CN108368148A publication Critical patent/CN108368148A/zh
Application granted granted Critical
Publication of CN108368148B publication Critical patent/CN108368148B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201680072731.4A 2016-04-21 2016-07-27 5-氮杂胞苷的糖部分甲硅烷基醚衍生物 Active CN108368148B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2016-085145 2016-04-21
JP2016085145 2016-04-21
PCT/JP2016/065660 WO2017183215A1 (ja) 2016-04-21 2016-05-27 ５－アザシチジン類の糖部シリルエーテル誘導体
JPPCT/JP2016/065660 2016-05-27
PCT/JP2016/072010 WO2017183217A1 (ja) 2016-04-21 2016-07-27 ５－アザシチジン類の糖部シリルエーテル誘導体

Publications (2)

Publication Number Publication Date
CN108368148A CN108368148A (zh) 2018-08-03
CN108368148B true CN108368148B (zh) 2021-11-05

Family

ID=60115962

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680072731.4A Active CN108368148B (zh) 2016-04-21 2016-07-27 5-氮杂胞苷的糖部分甲硅烷基醚衍生物

Country Status (5)

Country Link
EP (2) EP3543249A1 (enExample)
JP (1) JP2017197539A (enExample)
KR (1) KR102579485B1 (enExample)
CN (1) CN108368148B (enExample)
WO (2) WO2017183215A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019160127A1 (ja) * 2018-02-19 2019-08-22 大原薬品工業株式会社 Ｄｎｍｔ阻害剤の用途
CN112638422B (zh) * 2018-10-30 2023-03-17 大原药品工业株式会社 医药组合物
JPWO2021060341A1 (enExample) * 2019-09-26 2021-04-01
WO2022031759A1 (en) * 2020-08-04 2022-02-10 Herophilus, Inc. Decitabine induced mecp2 expression and uses thereof
WO2022181514A1 (ja) * 2021-02-23 2022-09-01 大原薬品工業株式会社 慢性骨髄性白血病幹細胞阻害剤

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050666A1 (en) * 2002-11-29 2004-06-17 Amedis Pharmaceuticals Ltd. Silicon compounds useful in cancer therapy
CN101282986A (zh) * 2005-09-29 2008-10-08 苏伯俭股份有限公司 其中结合5-氮杂-胞嘧啶的寡核苷酸类似物
CN102010455A (zh) * 2009-09-05 2011-04-13 山东新时代药业有限公司 一种地西他滨的制备方法
WO2013036846A2 (en) * 2011-09-09 2013-03-14 Koronis Pharmaceuticals, Incorporated N4 derivatives of deoxycytidine prodrugs
CN103619864A (zh) * 2011-03-31 2014-03-05 细胞基因国际有限公司 5-氮杂胞苷的合成
WO2016057828A1 (en) * 2014-10-08 2016-04-14 Epigenetics Pharma Llc Silylated pyrimidine prodrugs and methods of their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3816619A (en) * 1965-08-25 1974-06-11 Upjohn Co Ladakamycin and process for preparing same
CH527207A (de) 1968-05-08 1972-08-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
AU2003302624A1 (en) * 2002-11-29 2004-06-23 Amedis Pharmaceuticals Ltd. Silicon compounds
KR100897924B1 (ko) 2002-12-10 2009-05-18 엘지엔시스(주) 금융통합단말기 프린터부의 용지가이드 장치
KR100866399B1 (ko) 2002-12-10 2008-11-03 엘지엔시스(주) 매체자동지급기의 모듈부 스톱퍼장치
KR101922702B1 (ko) 2016-05-10 2018-11-29 주식회사 씨엔제이 기판용 필름의 재활용 칩 제작방법 및 장치

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050666A1 (en) * 2002-11-29 2004-06-17 Amedis Pharmaceuticals Ltd. Silicon compounds useful in cancer therapy
CN101282986A (zh) * 2005-09-29 2008-10-08 苏伯俭股份有限公司 其中结合5-氮杂-胞嘧啶的寡核苷酸类似物
CN102010455A (zh) * 2009-09-05 2011-04-13 山东新时代药业有限公司 一种地西他滨的制备方法
CN103619864A (zh) * 2011-03-31 2014-03-05 细胞基因国际有限公司 5-氮杂胞苷的合成
WO2013036846A2 (en) * 2011-09-09 2013-03-14 Koronis Pharmaceuticals, Incorporated N4 derivatives of deoxycytidine prodrugs
WO2016057828A1 (en) * 2014-10-08 2016-04-14 Epigenetics Pharma Llc Silylated pyrimidine prodrugs and methods of their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Establishment and functional validation of a structural homology model for human DNA methyltransferase 1";Pawel Siedlecki, et al.;《Biochemical and Biophysical Research Communications》;20031231;第306卷;第558-563页 *
RAMON GÜIMIL GARCÍA，et al.."Synthesis of Oligonucleotide Inhibitors of DNA (Cytosine-C5) Methyltransferase Containing 5-Azacytosine Residues at Specific Sites".《ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT》.2001,第11卷第369-378页. *

Also Published As

Publication number Publication date
CN108368148A (zh) 2018-08-03
WO2017183215A1 (ja) 2017-10-26
EP3252067A1 (en) 2017-12-06
EP3252067A4 (en) 2017-12-06
WO2017183217A1 (ja) 2017-10-26
JP2017197539A (ja) 2017-11-02
EP3543249A1 (en) 2019-09-25
KR102579485B1 (ko) 2023-09-20
EP3252067B1 (en) 2019-05-29
KR20180134835A (ko) 2018-12-19

Similar Documents

Publication Publication Date Title
CN108368148B (zh) 5-氮杂胞苷的糖部分甲硅烷基醚衍生物
KR0177372B1 (ko) 3'-치환 뉴클레오시드 유도체
JP6162349B1 (ja) ５−アザシチジン類の糖部シリルエーテル誘導体
KR101869940B1 (ko) 암 치료를 위한 제불라린 또는 1'-시아노-시타라빈 및 단쇄 지방산을 포함하는 상호 전구약물
WO2018199048A1 (ja) ヌクレオシド系抗がん剤または抗ウィルス剤の５'位モノ燐酸ジベンジルエステル誘導体
JP6956937B2 (ja) Ｄｎｍｔ阻害剤の用途
CN108290920B (zh) 5-氮杂胞苷或2’-脱氧-5-氮杂胞苷的5’-二苄基磷酸酯
KR20070103012A (ko) 신규 피리미딘 뉴클레오시드화합물 또는 그의 염
US8759323B2 (en) Protein phosphatase inhibitor
KR20090033875A (ko) 3＇-에티닐시티딘 유도체
US10227374B2 (en) Silyl etherified derivatives of 5-azacytidines in carbohydrate moiety
WO2018230479A1 (ja) ヌクレオシド系抗がん剤又は抗ウィルス剤の５'位シリルエーテル誘導体
JP7496112B2 (ja) プロドラッグ及び医薬組成物
EP4059938A1 (en) Imidazoquinoline substituted phosphoric ester agonist, and preparation therefor and application thereof
US11173174B2 (en) DNMT inhibitor as solid tumor therapeutic drug
HK1130496B (en) 3'-ethynylcytidine derivative

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant